In Re PEN

Court of Appeals for the Federal Circuit·Decided June 12, 2024·No. 23-2282·Unpublished

Opinion

NOTE: This disposition is nonprecedential.

United States Court of Appeals for the Federal Circuit

IN RE: THE PEN,

Appellant

2023-2282

Appeal from the United States Patent and Trademark Office, Patent Trial and Appeal Board in No. 16/104,878.

Decided: June 12, 2024

THE PEN, West Hollywood, CA, pro se.

MARY L. KELLY, Office of the Solicitor, United States Patent and Trademark Office, Alexandria, VA, for appellee Katherine K. Vidal. Also represented by KAKOLI CAPRIHAN, WILLIAM LAMARCA, AMY J. NELSON, FARHEENA YASMEEN RASHEED.

2 IN RE: PEN

Before MOORE, Chief Judge, TARANTO, Circuit Judge, and CECCHI, District Judge. ∗ PER CURIAM.

The Pen (Pen) appeals a decision of the Patent Trial and Appeal Board (Board) affirming an Examiner’s rejection of claims 1, 4–6, 10, and 13 of U.S. Patent Application No. 16/104,878 as unpatentable under 35 U.S.C § 112(a) for lack of enablement. We have jurisdiction under 28 U.S.C. § 1295(a)(4). For the reasons discussed below, we affirm.

BACKGROUND

The ’878 Application is directed to metallole polymers with a polycyclic repeating unit backbone. Independent claim 1 is illustrative of claims at issue:

1. A polycylic metallole heteroatom rich conductive long chain polymer comprised of the repeating unit in the brackets in either formula 2 below, where n is the number of repeating units, M is the heteroatom , R is any substituent, and x is the number of R substituents, depicted as

∗ Honorable Claire C. Cecchi, District Judge, United States District Court for the District of New Jersey, sitting by designation.

IN RE: PEN 3

or formula 4 below, where n is the number of repeating units, M is the heteroatom, R is any substituent , and x is the number of R substituents, depicted as

where there are more than eight repeating units, and where the metallole heteroatom is nitrogen.

J.A. 132–33.

The Examiner issued a final rejection for claims 1, 4– 6, 10, and 13 of the ’878 Application pursuant to 35 U.S.C. § 112(a) for failing to comply with the enablement requirement . 1 J.A. 142–43. The Examiner applied the enablement factors detailed in In re Wands, 858 F.2d 731, 737 (Fed. Cir. 1988), and discussed reasons why a skilled artisan would not be able to make and use the claimed invention without undue experimentation. J.A. 143–45. Specifically, the Examiner determined the claims were not enabled because “R” is not limited to any substituent “n” can be any number despite the closest prior art only achieving a length of 8 units and the amount of direction provided

1 Claims 2, 3, 7–9, 11, 12, 14, and 15 were withdrawn from consideration due to a requirement for election of species . J.A. 87, 141. Claim 5 was also rejected as indefinite, but that rejection was reversed by the Board and not at issue here. J.A. 9.

4 IN RE: PEN

in the written description regarding material selection and synthetic routes was insufficient.

Pen appealed to the Board. The Board affirmed the Examiner’s § 112(a) rejection. J.A. 9. In affirming, the Board noted the Examiner’s Wands factor analysis and concluded the Examiner set forth a reasonable explanation why the full scope of the claims was not enabled and Pen failed to identify reversible error. Id. at 6–9. Pen timely appeals.

DISCUSSION

Whether a claim satisfies the enablement requirement is a question of law that may be based on underlying factual findings. Medytox, Inc. v. Galderma S.A., 71 F.4th 990, 996 (Fed. Cir. 2023) (citing Alcon Rsch. Ltd. v. Barr Lab’ys, Inc., 745 F.3d 1180, 1188, 1190 (Fed. Cir. 2014)). We review the Board’s legal conclusions de novo and its factual findings for substantial evidence. In re Kotzab, 217 F.3d 1365, 1369 (Fed. Cir. 2000). “If the evidence in record will support several reasonable but contradictory conclusions , we will not find the Board’s decision unsupported by substantial evidence simply because the Board chose one conclusion over another plausible alternative.” In re Jolley, 308 F.3d 1317, 1320 (Fed. Cir. 2002).

Section 112(a) sets forth the enablement requirement:

“The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention .” 35 U.S.C. § 112(a). “If a patent claims an entire class of processes, machines, manufactures, or compositions of matter, the patent’s specification must enable a person skilled in the art to make and use the entire class. In other words, the specification must enable the full scope of the

IN RE: PEN 5

invention as defined by the claims.” Amgen Inc. v. Sanofi, 143 S. Ct. 1243, 1254 (2023). In short, the more you claim, the more you must explain.

I.

Pen argues the Board erred in relying on precedent not cited by the Examiner and asserts the ’878 Application is factually distinguishable. We do not agree. The Board correctly cited case law from this Court and the Supreme Court in explaining the enablement requirement. J.A. 7, 8 (citing Genentech, Inc. v. Novo Nordisk A/S, 108 F.3d 1361, 1365 (Fed. Cir. 1997); Amgen, 143 S. Ct. at 1254). The Board also correctly set forth the evidentiary burdens for showing enablement in its citation to In re Wright, 999 F.2d 1557, 1561–62 (Fed. Cir. 1993). J.A. 7. Contrary to Pen’s allegations, the Board did not analogize to the facts of any cases to present rejections beyond those addressed by the Examiner. The Board explained the law underlying the Examiner’s rejection, which is not a new ground of rejection . In re Biedermann, 733 F.3d 329, 337 (Fed. Cir. 2013) (“A new ground of rejection, however, generally will not be found based on the Board ‘further explain[ing] the Examiner ’s rejection’ or the Board’s thoroughness in responding to an applicant’s argument.” (alteration in original) (quoting In re Jung, 637 F.3d 1356, 1364–65 (Fed. Cir. 2011))).

Pen, however, in attempting to distinguish the cited cases, presents a new argument in this appeal. Pen alleges the “R” group claimed in the ’878 Application has no effect on the purpose of the invention, conductivity. This is counterfactual , Pen argues, to the facts of Amgen and Wright because the structural variations in those cases would render the final product nonfunctional. Because Pen never made this argument below, it is forfeited. In re Watts, 354 F.3d 1362, 1367 (Fed. Cir. 2004) (“Just as it is important that the PTO in general be barred from raising new arguments on appeal to justify or support a decision of the Board, it is important that the applicant challenging a 6 IN RE: PEN

decision not be permitted to raise arguments on appeal that were not presented to the Board.” (footnote omitted)).

II.

Pen argues the Board erred in raising a new rejection based on the claimed polymer having no upper limit to the number of repeating units. 2 We do not agree. The Examiner specifically noted the prior art only supported an “n” of 8 conjugated units, whereas the ’878 Application claimed an “n” of more than 8, at least 50, and at least 1000. J.A. 143. Pen acknowledged this finding by the Examiner in his appeal brief to the Board. J.A. 156. The Examiner reiterated the same finding in the Examiner’s Answer to Pen’s appeal brief. See, e.g., J.A. 181–82, 184. The Board did not raise this rejection for the first time. It properly considered the findings made by the Examiner.

III.

Pen argues the Board erred in affirming the Examiner ’s enablement analysis. We do not agree. The Examiner , in both the Final Rejection and the Examiner’s Answer, analyzed each Wands factor and concluded undue experimentation would be required to make and use the full scope of the claims of the ’878 Application. J.A. 143– 45, 181–86.

Free access — add to your briefcase to read the full text and ask questions with AI

In Re PEN, (Fed. Cir. 2024).

In Re PEN (In Re PEN) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

In Re Jung
637 F.3d 1356 (Federal Circuit, 2011)
In Re Stephen E. Wright
999 F.2d 1557 (Federal Circuit, 1993)
In Re Werner Kotzab
217 F.3d 1365 (Federal Circuit, 2000)
In Re Scott T. Jolley
308 F.3d 1317 (Federal Circuit, 2002)
In Re Lavaughn F. Watts, Jr
354 F.3d 1362 (Federal Circuit, 2004)
Inre: Biedermann
733 F.3d 329 (Federal Circuit, 2013)
Alcon Research, Ltd. v. Barr Laboratories, Inc.
745 F.3d 1180 (Federal Circuit, 2014)
Medytox, Inc. v. Galderma S.A.
71 F.4th 990 (Federal Circuit, 2023)